Partners Capital Investment Group’s UroGen Pharma URGN Stock Holding History

Partners Capital Investment Group’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$566K	Hold	15,384	–	–	0.02%	137
2026 Q1	$277K	Hold	15,384	–	–	0.01%	147
2025 Q4	$360K	Hold	15,384	–	–	0.01%	139
2025 Q3	$307K	Hold	15,384	–	–	0.01%	148
2025 Q2	$211K	Hold	15,384	–	–	0.01%	154
2025 Q1	$170K	Buy	+15,384	New	+$164K	﹤0.01%	181
2024 Q4	–	Sell	-15,384	Closed	-$195K	–	162
2024 Q3	$195K	Hold	15,384	–	–	﹤0.01%	170
2024 Q2	$258K	Buy	+15,384	New	+$219K	﹤0.01%	173
2024 Q1	–	Sell	-15,384	Closed	-$231K	–	261
2023 Q4	$231K	Hold	15,384	–	–	0.01%	252
2023 Q3	$216K	Hold	15,384	–	–	0.01%	224
2023 Q2	$159K	Buy	+15,384	New	+$170K	﹤0.01%	215

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Partners Capital Investment Group's URGN Position: Q2 2026 in Review

Partners Capital Investment Group held its UroGen Pharma (URGN) position steady in Q2 2026 at 15,384 shares worth $566K. The position accounts for 0.02% of the portfolio, ranked #137.

Partners Capital Investment Group first reported a position in URGN in Q2 2023 and has held it in 11 quarters since. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Partners Capital Investment Group held 15,384 shares of UroGen Pharma worth $566K as of Q2 2026.
Partners Capital Investment Group left its UroGen Pharma share count unchanged in Q2 2026.
UroGen Pharma made up 0.02% of Partners Capital Investment Group's portfolio in Q2 2026, its #137 holding.
Partners Capital Investment Group first reported a position in UroGen Pharma in Q2 2023 and has held it in 11 quarters since.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Partners Capital Investment Group's 13F filing for Q2 2026, filed 13 Aug 2026.